Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic PEG-rhG-CSF During Chemoradiotherapy for Cervical Cancer
ChiCTR1900026309Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of pegfilgrastim and filgrastim in Cervical Cancer (CC) (3 arms), sponsored by Henan Cancer Hospital. Primary endpoint: absolute neutrophil count. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900026309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026309.